Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

INCIVEK

TELAPREVIR

Standard Dose
375MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview INCIVEK is listed in Drugs@FDA under application 201917 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient TELAPREVIR Form and strength TABLET;ORAL - 375MG Sponsor VERTEX PHARMS Submission history Latest submission status date: 2014-03-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview INCIVEK is listed in Drugs@FDA under application 201917 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient TELAPREVIR Form and strength TABLET;ORAL - 375MG Sponsor VERTEX PHARMS Submission history Latest submission status date: 2014-03-25 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.